Showing results (41-50 of 65) with videos related to
Sort By:
Pageof 7
International Journal of Clinical Oncology|November 5, 2018
Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patientsNorikazu Masuda, Kenichi Inoue, Rikiya Nakamura, et al.Breast Cancer Research and Treatment|March 22, 2023
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapyHiroji Iwata, Yutaka Yamamoto, Takehiko Sakai, et al.Genes, Chromosomes & Cancer|November 7, 2024
Sporadic Breast Angiosarcoma With MYC Amplification on Extrachromosomal Circular DNA Detected Using Nanopore Sequencing in an Adolescent FemaleNaohiro Makise, Jason Lin, Hajime Kageyama, et al.BMC Cancer|April 27, 2023
The impact of PIK3CA mutations and PTEN expression on the effect of neoadjuvant therapy for postmenopausal luminal breast cancer patientsShouko Hayama, Rikiya Nakamura, Takayuki Ishige, et al.Breast Cancer (Tokyo, Japan)|June 17, 2026
Prognosis of ER-positive, HER2-negative postmenopausal early breast cancer patients based on response to neoadjuvant endocrine therapy and multigene assay results: findings from the NEOS trialHiroji Iwata, Norikazu Masuda, Yutaka Yamamoto, et al.Breast Cancer (Tokyo, Japan)|October 8, 2024
Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trialEriko Tokunaga, Hiroji Iwata, Mitsuya Itoh, et al.Journal of Global Oncology|August 24, 2017
PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety and Efficacy in Asian PatientsHiroji Iwata, Seock-Ah Im, Norikazu Masuda, et al.European Journal of Cancer (Oxford, England : 1990)|February 1, 2019
A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanesKan Yonemori, Akihiko Shimomura, Hiroyuki Yasojima, et al.Breast Cancer Research and Treatment|March 19, 2026
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 studyNorikazu Masuda, Hiroyuki Yasojima, Hiroko Bando, et al.Investigational New Drugs|August 25, 2020
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study)Toshinari Yamashita, Hidetoshi Kawaguchi, Norikazu Masuda, et al.Pageof 7